Parsons Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Parsons Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Hold	21,645	–	–	0.01%	416
2025 Q4	$261K	Hold	21,645	–	–	0.01%	420
2025 Q3	$294K	Hold	21,645	–	–	0.02%	388
2025 Q2	$139K	Hold	21,645	–	–	0.01%	433
2025 Q1	$76.6K	Hold	21,645	–	–	﹤0.01%	429
2024 Q4	$81.8K	Sell	21,645 -300	-1%	-$1.41K	﹤0.01%	436
2024 Q3	$71.1K	Hold	21,945	–	–	﹤0.01%	438
2024 Q2	$41.7K	Hold	21,945	–	–	﹤0.01%	435
2024 Q1	$62.3K	Hold	21,945	–	–	﹤0.01%	433
2023 Q4	$323K	Hold	21,945	–	–	0.02%	363
2023 Q3	$402K	Hold	21,945	–	–	0.03%	318
2023 Q2	$473K	Hold	21,945	–	–	0.04%	303
2023 Q1	$644K	Sell	21,945 -5,200	-19%	-$181K	0.05%	265
2022 Q4	$1M	Buy	27,145 +10,280	+61%	+$365K	0.08%	202
2022 Q3	$475K	Buy	+16,865	New	+$421K	0.04%	279

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Parsons Capital Management's AMLX Position: Q1 2026 in Review

Parsons Capital Management held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 21,645 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #416.

Parsons Capital Management first reported a position in AMLX in Q3 2022 and has held it in 15 quarters since. The position peaked at $1M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Parsons Capital Management held 21,645 shares of Amylyx Pharmaceuticals worth $301K as of Q1 2026.
Parsons Capital Management left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
Amylyx Pharmaceuticals made up 0.01% of Parsons Capital Management's portfolio in Q1 2026, its #416 holding.
Parsons Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Parsons Capital Management's Amylyx Pharmaceuticals position peaked at $1M in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Parsons Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.